Index
Module 12 • Cardiology
Cardiovascular Critical Care II
54%
Data Tables
Cardiovascular Critical Care II
Patrick M. Wieruszewski ~3 min read Module 12 of 20
32
/ 59

Cardiovascular Critical Care II

Medication

Typical Dosing

Range

(mcg/kg/min)

Clinical Pearls

Dopamine

2–20

In general, dose-related receptor activity:

2–5 mcg/kg/min dopamine receptor,

5–10 mcg/kg/min Ξ²1-receptor,

> 10 mcg/kg/min Ξ±1-receptor

Does not provide exclusive receptor activity across dosing ranges and, thus,

can be arrhythmogenic at any dose

Use cautiously in patients with a history of heart disease or arrhythmias

Useful for patients with bradycardia and hypotension

Dobutamine

2–20

Predominance of inotropic properties but with activity on Ξ²1 > Ξ²2 > Ξ±1-receptor

Used to treat low cardiac output

Ξ±1-agonist and Ξ²2-agonist counterbalance, leading to little change in systemic

vascular resistance

Can lead to vasodilation in select patients

Less systemic or pulmonary vasodilation than milrinone

More tachycardia than milrinone but similar risk of ventricular arrhythmias

Use cautiously in patients with a history of arrhythmias

Milrinone

0.25–0.75

Phosphodiesterase type 3 inhibitor leading to increased intracellular cAMP

leading to influx of calcium and subsequently inotropy and chronotropy

Used to treat low cardiac output

Loading dose rarely used because of significant systemic hypotension

Longer duration of activity than dobutamine

Accumulates in renal dysfunction

More systemic and pulmonary vasodilation than dobutamine

Less tachycardia than dobutamine but similar risk of ventricular arrhythmias

Use cautiously in patients with a history of arrhythmias

aSee chapter on shock for a detailed discussion regarding selection of agent, dosing, pharmacology, and clinical considerations.

SBP = systolic blood pressure

ii.

Glucose management (Circulation 2010;122:S768-786; Circulation 2008;118:2452-83)

(a)Avoidance of severe hypoglycemia (40 mg/dL or less)
(b)Target moderate glucose control: 144–180 mg/dL
(c)May require continuous insulin infusion to maintain goals

iii.

Seizure control/prevention (Neurology 1988;38:401-5; JAMA 1985;253:1420-6): Myoclonus

and seizures, or both, can occur in up to 35% of adult patients who achieve ROSC and are more

common in those who remain comatose. Electrographic patterns seen in the patient population

include electrographic seizures, status epilepticus, and ictal-interictal continuum patterns

(Circulation 2024;149:e254-73).
(a)Clonazepam, valproic acid, and levetiracetam are all effective for myoclonus, but

clonazepam should be considered first line.

(b)Benzodiazepines, phenytoin, valproic acid, propofol, and barbiturates are all effective for

post–cardiac arrest seizures. Seizures and status epilepticus are treated similarly to non-

cardiac arrest populations. For dosing and monitoring guidelines, see the Status Epilepticus

section of the Neurocritical Care chapter.

Table 6. Common Vasoactive Agents Used After Cardiac Arrest (continued)
Ψ΄Ψ±Ψ­ Ψ§Ω„ΩΩŠΨ―ΩŠΩˆ Ψ§Ω„ΨͺΨΉΩ„ΩŠΩ…ΩŠ β€” Ω…Ψ²Ψ§Ω…Ω†Ψ© Ω…ΨΉ Ψ§Ω„Ω€ PDF
Ψ¨Ψ―Ψ‘ Ψ§Ω„ΨͺΨ΄ΨΊΩŠΩ„ Ω…Ω†: Ψ§Ω„Ψ―Ω‚ΩŠΩ‚Ψ© 31 فΨͺΨ­ ΨΉΩ„Ω‰ YouTube